NO20040659L - Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom - Google Patents

Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom

Info

Publication number
NO20040659L
NO20040659L NO20040659A NO20040659A NO20040659L NO 20040659 L NO20040659 L NO 20040659L NO 20040659 A NO20040659 A NO 20040659A NO 20040659 A NO20040659 A NO 20040659A NO 20040659 L NO20040659 L NO 20040659L
Authority
NO
Norway
Prior art keywords
isoxazolopyridinones
parkinson
disease
treatment
Prior art date
Application number
NO20040659A
Other languages
English (en)
Norwegian (no)
Other versions
NO20040659D0 (no
Inventor
Samuel Hintermann
Bastian Hengerer
Ulrike Von Krosigk
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20040659L publication Critical patent/NO20040659L/no
Publication of NO20040659D0 publication Critical patent/NO20040659D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20040659A 2001-08-15 2004-02-13 Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom NO20040659D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds
PCT/EP2002/009134 WO2003015780A2 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
NO20040659L true NO20040659L (no) 2004-02-13
NO20040659D0 NO20040659D0 (no) 2004-02-13

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040659A NO20040659D0 (no) 2001-08-15 2004-02-13 Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom

Country Status (24)

Country Link
US (1) US7087756B2 (ko)
EP (1) EP1418912B1 (ko)
JP (1) JP2005501847A (ko)
KR (1) KR20040029429A (ko)
CN (1) CN100384418C (ko)
AR (1) AR036351A1 (ko)
AT (1) ATE355059T1 (ko)
BR (1) BR0211903A (ko)
CA (1) CA2454762A1 (ko)
CO (1) CO5560566A2 (ko)
DE (1) DE60218484T2 (ko)
EC (1) ECSP044971A (ko)
ES (1) ES2282467T3 (ko)
GB (1) GB0119911D0 (ko)
HU (1) HUP0401325A3 (ko)
IL (1) IL160018A0 (ko)
MX (1) MXPA04001419A (ko)
NO (1) NO20040659D0 (ko)
PE (1) PE20030356A1 (ko)
PL (1) PL366848A1 (ko)
PT (1) PT1418912E (ko)
RU (1) RU2004107847A (ko)
WO (1) WO2003015780A2 (ko)
ZA (1) ZA200400525B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002102807A1 (ja) * 2001-06-14 2004-09-30 萬有製薬株式会社 新規イソキサゾロピリドン誘導体及びその用途
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
CN101466380A (zh) * 2006-02-16 2009-06-24 麦克莱恩医院 治疗帕金森病的方法和组合物
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
EP2376079B1 (en) * 2009-01-13 2016-08-10 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
KR20160060688A (ko) 2013-09-25 2016-05-30 반 안델 리서치 인스티튜트 고도로 강력한 글루코코르티코이드
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
WO2018071736A1 (en) 2016-10-14 2018-04-19 Van Andel Research Institute Structures and mechanism for the design of highly potent glucocorticoids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
US4238616A (en) * 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
JPWO2002102807A1 (ja) * 2001-06-14 2004-09-30 萬有製薬株式会社 新規イソキサゾロピリドン誘導体及びその用途

Also Published As

Publication number Publication date
BR0211903A (pt) 2004-09-21
EP1418912A2 (en) 2004-05-19
EP1418912B1 (en) 2007-02-28
DE60218484T2 (de) 2007-11-15
PT1418912E (pt) 2007-05-31
CN100384418C (zh) 2008-04-30
ECSP044971A (es) 2004-03-23
IL160018A0 (en) 2004-06-20
WO2003015780A2 (en) 2003-02-27
ZA200400525B (en) 2005-04-01
PE20030356A1 (es) 2003-05-14
KR20040029429A (ko) 2004-04-06
CN1635889A (zh) 2005-07-06
JP2005501847A (ja) 2005-01-20
GB0119911D0 (en) 2001-10-10
WO2003015780A3 (en) 2003-11-13
ES2282467T3 (es) 2007-10-16
RU2004107847A (ru) 2005-05-10
AR036351A1 (es) 2004-09-01
ATE355059T1 (de) 2006-03-15
US7087756B2 (en) 2006-08-08
MXPA04001419A (es) 2004-05-27
CA2454762A1 (en) 2003-02-27
HUP0401325A2 (hu) 2004-10-28
US20040248893A1 (en) 2004-12-09
NO20040659D0 (no) 2004-02-13
CO5560566A2 (es) 2005-09-30
DE60218484D1 (de) 2007-04-12
WO2003015780A8 (en) 2004-05-21
HUP0401325A3 (en) 2005-09-28
PL366848A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1767197A3 (en) Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
NO20052698D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
NO20034169L (no) MCH-antagonister og deres anvendelse ved behandling av fedme
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
NO20034437L (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
NO20006357D0 (no) Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
NO20011409L (no) Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20040659D0 (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS7203A (is) 4[píperidín-4-ýliden-(3-karbamólýlfenýl)metýl]bensamíðafleiður og notkun þeirra til að meðhöndla verki, mænuskaða eða maga- og garnasjúkdóma
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
NO20020031D0 (no) Dihydrobenzodiazepiner og deres anvendelse ved behandling av dyslipidemi
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
NO20006358D0 (no) Anvendelse av optisk ren (-)-norcisaprid ved behandling av apné, bulimi og andre sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application